CCRM
Cynthia Elias PhD has held various leadership roles in manufacturing operations, biologics manufacturing, and vaccine production at companies such as CCRM, National Research Council Canada, and Sanofi Pasteur. With a background in chemical engineering and biotechnology, Cynthia has managed operations teams, budgets, and cross-functional projects, showcasing expertise in areas such as cell culture, GMP operations, and Quality Systems. Additionally, Cynthia has a strong research background with experience at institutions such as University of Colorado Boulder and Institute Of Chemical Technology.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.